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Higher age at diagnosis of hemochromatosis is
the strongest predictor of the occurrence of
hepatocellular carcinoma in the Swiss
hemochromatosis cohort
A prospective longitudinal observational study
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∗
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Abstract
Hereditary hemochromatosis (HH) is the most common genetic disease in Caucasians which is characterized by an increased
intestinal iron absorption, resulting into a progressive accumulation of iron in organs including liver, heart, and pancreas, leading to
their progressive dysfunction. Hepatocellular carcinoma (HCC) is a long-term complication of HH, which contributes to increased
mortality.
We evaluated the risk factors of HCC in a prospective cohort of Swiss hemochromatosis patients with a long-term follow-up.
We included 147 patients with the mean age at diagnosis of 48 years, in whom 70% were men. Overall, 9% of the patients
developed HCC during the mean follow-up time of 14 years (range 1–40 years). Patients with HCC had higher age at diagnosis (61±
11 vs 47±13 years, P= .003), more frequently liver cirrhosis on biopsy (90% vs 37.5%, P= .004), and higher serum ferritin levels
[3704 (Q1:2025, Q3:4463) vs 1338 (Q1:691, Q3:2468) mg/L, P< .001], they needed more iron removed by phlebotomy until its
depletion [8.9 (Q1:7.2, Q3:10.1) vs 3.8 (Q1:1.6, Q3:8.9) g, P= .029], compared to non-HCC patients. After adjustment for possible
confounders, only higher age at diagnosis remained signiﬁcantly associated with HCC development (odds ratio 1.19, 95% CI 0.056–
0.397, P= .001, per year).
Higher age at diagnosis showed the strongest association with the occurrence of HCC in Swiss hemochromatosis patients.
Patients whowere diagnosed at a higher age andwith a high iron overload (serum ferritin levels>1000mg/L) require regular screening
even if they have no liver cirrhosis.
Abbreviations: AASLD=American Association for the Study of Liver Diseases, AFP= alpha-fetoprotein, BMI= bodymass index,
CT = computed tomography, DNA = deoxyribonucleic acid, HCC = hepatocellular carcinoma, HFE = high iron Fe, HH = hereditary
hemochromatosis, MCP=metacarpophalangeal, MRI =magnetic resonance imaging, NAFLD= nonalcoholic fatty liver disease, OR
= odds ratio.
Keywords: hemochromatosis, hepatocellular carcinoma, risk factor
1. Introduction
Hereditary hemochromatosis (HH), an autosomal recessive
disease, is the most common inborn disease in Caucasians,
particularly in those with Nordic and Celtic ancestry, with the
prevalence of homozygosity of approximately 0.5% and of
heterozygosity about 10%.[1–4] The most frequent causative
mutation is a substitution of tyrosine for cysteine at position 282
of the high iron Fe (HFE) protein product (C282Y); the second
frequent mutation is a substitution of aspartate for histidine at
position 63 (H63D).[5,6]
HH is characterized by an increased intestinal iron absorption,
which results into a progressive accumulation of iron in organs
including liver, heart, and pancreas, leading to their progressive
dysfunction.[3,7] Hepcidin, the most important regulator of
systemic iron metabolism, is inﬂuenced by body iron stores,
erythropoietic activity, and hypoxia, and plays the dominant role
in controlling iron absorption. Its serum levels are decreased in
HFE hemochromatosis.[8]
Hepatocellular carcinoma (HCC) is a dreaded long-term
complication of HH, as it largely contributes to the increased
mortality in patients with HH.[9] Its occurrence has been
associated with a high iron overload and shown to be mostly
a consequence of homozygosity of the C282Y mutation.[10] The
major pathogenic mechanism of HCC development is the
oxidative deoxyribonucleic acid (DNA) damage, which is
induced by the formation of hydroxyl radicals due to the
catalytic activity of iron.[11]
To prevent this complication, HH patients at risk for
HCC need to be monitored more closely and treated more
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intensively.[9,12,13] However, to identify the risk factors for HCC
development and to estimate the prevalence of HCC remains an
unmet clinical need, because of controversial reports in previous
studies.[9,12–17] In our nationwide long-term study of a large
cohort with genetically proven HH patients, who were regularly
followed-up at our specialized iron metabolism tertiary care
center or in the primary care, we aimed to elucidate these
questions.
2. Methods
This is an analysis of the prospective Swiss hemochromatosis
cohort. The study was conducted in accordance with the
principles of the Helsinki Declaration. Approval for this study
was obtained from the Ethics Committee of the Canton of
Zurich, Switzerland, (KEK 2010-0364). All patients participating
in the study gave written informed consent.
2.1. Study population and the HH diagnosis
We contacted the patients during the routine clinical visits at the
University Hospital Zurich or via the Swiss Hemochromatosis
patient’s organization and suggested to participate in this study.
The patients included in this analysis were diagnosed between
1971 and 2013.
The patients had been initially diagnosed as having HH either
due to clinical or biochemical or histological signs of iron
overload or through family screening. Iron overload was deﬁned
as elevated serum ferritin (>300mg/L for men, >200mg/L for
women) and/or elevated transferrin saturation (>50% for men,
>45% for women). The diagnosis of HH was genetically
conﬁrmed in all patients: C282Y homozygotes, C282Y/H63D
compound heterozygotes or H63D homozygotes.
These consecutive HH patients were registered into the Swiss
Hemochromatosis database, included into the prospective cohort
and were offered routine examinations including a clinical
assessment, laboratory blood analyses, and annual liver imaging
using ultrasound, computed tomography scan, or magnetic
resonance imaging (MRI).
The following features were considered clinical manifesta-
tions of HH: metacarpophalangeal (MCP) arthropathy,
diabetes mellitus, hepatopathy, cardiomyopathy, and hypo-
gonadism. The presence of arthropathy was assessed by
history and clinical examination. Hepatopathy was deﬁned
as either elevated liver enzymes (aspartate and/or alanine
transaminase above the upper limit of normal as indicated by
the corresponding laboratory) or positive liver histology.
Positive liver histology was deﬁned as portal-portal bridging
ﬁbrosis or cirrhosis, corresponding to grade 3 and 4 on a scoring
system from 0 to 4.[18,19] Cardiomyopathy was speciﬁed as
either dilated or restrictive cardiomyopathy with documented
cardiac iron overload. The diagnosis of hypogonadism was
based on typical clinical characteristics in combination with
low testosterone levels.
2.2. Data assessment
The following data were collected at the time of diagnosis of HH
and included into the present analysis: type of HFE-gene
mutation, age, sex, serum ferritin level, transferrin saturation,
elevation of transaminases, histological result of liver biopsy (if
available), and serologic testing for hepatitis B and C and clinical
manifestation.
The following variables were recorded during the course
of the disease and extracted from the medical records for
the present analysis: amount of iron removed through
phlebotomy until achievement of a serum ferritin level of
<300mg/L (assuming that 500 mL of blood removed corre-
spond to 250mg of iron), body mass index (BMI), date and
result of the most recent liver imaging, and the self-reported
amount of alcohol consumption. Considerable alcohol con-
sumption was deﬁned as intake of >20g (men) or >10g
(women) of ethanol per day.
If patients were followed by primary care physicians, their
medical records were obtained for this study.
2.3. Treatment and HCC diagnosis
All patients except one—who refused therapy—received treat-
ment with intensive phlebotomies from the time of diagnosis until
depletion of iron stores followed by maintenance phlebotomies
where necessary.
HCCwas suspected on the routine liver imaging and conﬁrmed
by biopsy in all patients. Patients without focal hepatic lesions on
imaging studies were considered negative for HCC.
2.4. Statistical analysis
Statistical analysis was performed using the IBM SPSS statistics
22 software package (34). Variables were compared using the
Student t test, the Mann-Whitney U test, or the Fisher exact test
(all 2-tailed). A P value of <.05 was considered signiﬁcant.
Multiple logistic regression was used to assess for the indepen-
dent effects of relevant variables on the outcome. To correct for
small sample bias and to deal with the problem of quasicomplete
separation, Firth’s penalized maximum likelihood estimation
(35) was used for the multiple logistic regression analysis
performed with R (36).
3. Results
3.1. Main clinical characteristics at the time of diagnosis
From 198 patients who were registered in the database, 51 were
excluded from the study for various reasons: 12 did not wish to
participate, 2 never had a documented iron overload, 3 did not
have HFE-related mutations, 1 patient suffered from concurrent
hereditary spherocytosis, and 33 patients could not be contacted
(Fig. 1). The main clinical and biochemical characteristics at the
time of diagnosis of the remaining 147 patients, who were
included into the present analysis, are shown in Table 1.
The mean age at diagnosis of HH was 48 years (range 18–89
years). Seventy percent of the patients were men. The majority of
patients (141/147) were C282Y homozygotes. Serum ferritin
levels ranged from 49 to 9180mg/L with a median of 1448mg/L.
Transferrin saturation was almost uniformly elevated. Twenty-
nine percent of patients did not show any organ-speciﬁc clinical
manifestations. The most frequent clinical manifestations were
MCP arthropathy, prevalent in 59 of 141 patients, and liver
disease, in 77 of 140 patients. Liver disease was mostly manifest
in the form of elevated liver enzymes. Overall, 70 patients
underwent liver biopsy, which was indicated by the treating
physicians independent of this study; 36 of biopsies showed
severe ﬁbrosis or cirrhosis. Diabetes mellitus was present in 8%,
hypogonadism in 7%, and cardiomyopathy in 1% of the
patients.
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3.2. HCC prevalence and clinical characteristics of the
HCC patients
The mean length of the follow-up was 14 years (range 1–40
years). Seventeen patients were excluded from this analysis,
because they had no liver imaging, 13 because they had deceased
and no information about their cause of death was available.
Ten patients were diagnosed with HCC, resulting in an overall
prevalence of 9%. All 10 patients were men and affected by a
homozygous C282Y mutation. None of them suffered from
concurrent chronic viral hepatitis. All 10 showed an MCP
arthropathy and elevated liver enzymes at the time of diagnosis of
HH. One patient had a normal liver biopsy, whereas the other 9
suffered from severe ﬁbrosis or cirrhosis. The time span from
diagnosis of HH to detection of HCC ranged from 0 to 30 years.
We further analyzed the prevalence of HCC among subgroups
stratiﬁed according to 2 of the most important risk factors—
ferritin and liver cirrhosis.[20,21] Of patients with a serum ferritin
level >1000mg/L at the time of diagnosis of HH, 14% (10/69)
developed HCC. When analyzing only patients with a serum
ferritin level higher than 2000mg/L, the resulting prevalence was
21% (7/34). Of those patients with positive liver histology, 33%
(9/27) were eventually diagnosed with HCC.
3.3. Risk factors for hepatocellular carcinoma
To determine the risk factors, we ﬁrst compared the main clinical
and biochemical characteristics at the time of diagnosis of HH
between patients with and without HCC. Table 2 shows this
juxtaposition with the statistical signiﬁcance of the differences
based on the univariate analysis. Patients with HCC were
signiﬁcantly older when diagnosedwithHH; the youngest patient
later suffering from HCC was 40 years old at the time of
diagnosis of HH. Serum ferritin levels were signiﬁcantly higher in
HCC patients, ranging from 1329 to 6807mg/L, as was the
amount of iron removed through the phlebotomy, ranging from 7
to 18g. The year of diagnosis did not differ signiﬁcantly. MCP
arthropathy, elevated liver enzymes, and histological signs of
liver cirrhosis were signiﬁcantly associated with HCC.
Because both, liver cirrhosis and HCC, have been reported to
be rare in patients with ferritin levels below 1000mg/
L,[12,13,20,22,23] we compared patients with higher ferritin levels
with and without HCC (Table 3) to evaluate possible indicators
for HCC in the patients most at risk. Higher age at diagnosis was
signiﬁcantly associated with HCC in the univariate analysis. The
other parameters showing a signiﬁcant association were higher
ferritin levels, liver ﬁbrosis on biopsy, and higher BMI. There was
no correlation between age and BMI.
To assess for the independent effect of the most relevant
variables associated with HCC, we performed a multiple logistic
regression analysis. The results are shown in Table 4. The
variables chosen for this analysis include those shown to be
signiﬁcant in Table 3 as well as those found positive in all HCC
patients (male sex, MCP arthropathy, elevated liver enzymes),
shown in Table 2. We further included considerable alcohol
intake, as it has previously been reported to cause liver cirrhosis
and HCC.[24] Liver histology was not included in this analysis
because of the relatively small number of patients who underwent
liver biopsy. As all patients with HCCwere men and had elevated
 
Registered in the Hemochromatosis Database: 
n=198 
Included into the analysis: 
n=147 
Excluded from analysis: 
Could not be contacted: n=33 
Refused to participate: n=12 
No documented iron overload: n=2 
No HFE-related mutations: n=3 
Concurrent hereditary spherocytosis: n=1 
Figure 1. Flow diagram of the Swiss Hemochromatosis Cohort. HFE= high iron Fe.
Table 1
Main clinical and biochemical characteristics at the time of
diagnosis of hereditary hemochromatosis.
All patients (n=147)
Age at diagnosis, y 48±14
Male sex, % (n) 70% (100)
Body mass index, kg/m2 25±4
Mutation: C282Y homozygotes, % (n) 96% (141/147)
C282Y/H63D compound heterozygotes, % (n) 3% (4/147)
H63D homozygotes, % (n) 1% (2/147)
Serum ferritin, mg/L (Q1, Q3) 1448 (727, 2285)
Transferrin saturation, % (Q1. Q3) 89% (79%, 95%)
Iron removed by phlebotomy until depletion
of iron stores, g (Q1, Q3)
4.1 (1.6, 9.5)
MCP-arthropathy, % (n) 42% (59/141)
Liver disease % (n) 55% (77/140)
Elevated liver enzymes, % (n) 53% (73/137)
Liver ﬁbrosis on biopsy
∗
, % (n) 51% (36/70)
Diabetes mellitus, %, (n) 8% (11/143)
Cardiomyopathy, % (n) 0.7% (1/143)
Hypogonadism, % (n) 7% (10/142)
Considerable alcohol intake†, % (n) 23% (33/145)
Values are means±1 standard deviation (SD) for normally distributed values and medians with ﬁrst
and third quartile for non-normally distributed values.
HH=hereditary hemochromatosis, MCP=metacarpophalangeal.
∗
Liver ﬁbrosis is deﬁned as either cirrhosis or severe, portal-portal bridging ﬁbrosis.
† Considerable alcohol intake is deﬁned as consumption of more than 1 standard drink (=10 g ethanol)
per day for women and >2 standard drinks for men.
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liver enzymes andMCP arthropathy, Firth’s penalized maximum
likelihood estimation[25] was used to deal with the issue of the
quasicomplete separation. The only variable still signiﬁcant in
this analysis was age at diagnosis.
To corroborate the ﬁnding of age as an independent risk factor,
we executed the same analysis including the results of the liver
biopsy. When analyzing all patients with a serum ferritin level
above 1000mg/Lwho underwent liver biopsy at diagnosis of HH,
Table 2
Comparison of main characteristics at the time of diagnosis of hereditary hemochromatosis between patients with and without
hepatocellular carcinoma.
HCC (n=10) no HCC (n=107) P
Age at diagnosis, y 61±11 (40–80) 47±13 (19–76) .003
Male sex, % (n) 100% (10) 69% (74) .06
Body mass index, kg/m2 27±3 25±4 .07
Serum ferritin, mg/L (Q1, Q3) 3704 (2025, 4463) 1338 (691, 2468) <.001
Iron removed by phlebotomy until depletion of iron stores, g (Q1, Q3) 8.9 (7.2, 10.1) 3.8 (1.6, 8.9) .03
MCP arthropathy, % (n) 80% (8/10) 44% (44/104) .04
Elevated liver enzymes, % (n) 100% (10/10) 53% (53/100) .005
Liver ﬁbrosis on biopsy
∗
, % (n) 90% (9/10) 37.5% (18/48) .004
Diabetes mellitus, %, (n) 10% (1/10) 7% (7/104) .53
Hypogonadism, % (n) 20% (2/10) 6% (6/104) .15
Considerable alcohol intake†, % (n) 20% (2/10) 26% (27/105) 1
Year of diagnosis (Q1, Q3) 2001 (1990, 2003) 1999 (1996, 2007) .48
Values are means±1 standard deviation (SD) for normally distributed values and medians with ﬁrst and third quartile for non-normally distributed values.
∗
Liver ﬁbrosis is deﬁned as either cirrhosis or severe, portal-portal bridging ﬁbrosis.
† Considerable alcohol intake is deﬁned as consumption of >1 standard drink (=10g ethanol) per day for women and >2 standard drinks for men.
HCC=hepatocellular carcinoma, HH=hereditary hemochromatosis, MCP=metacarpophalangeal.
Table 3
Comparison between patients with hepatocellular carcinoma and patients without hepatocellular carcinoma and serum ferritin>1000mg/L
at the time of diagnosis of hereditary hemochromatosis.
HCC (n=10) Ferritin ≥1000mg/mL, no HCC (n=59) P
Age at diagnosis, years (range) 61±11 (40–80) 48±10 (24–69) <.001
Male sex, % (n) 100% (10) 80% (47/59) .19
Body mass index, kg/m2 27±3 25±3 .01
Serum ferritin, mg/L (Q1, Q3) 3704 (2025, 4463) 2115 (1493, 2830) .03
MCP-arthropathy, % (n) 80% (8/10) 54% (32/59) .17
Elevated transaminases, % (n) 100% (10/10) 68% (39/57) .05
Liver ﬁbrosis on biopsy
∗
, % (n) 90% (9/10) 50% (16/32) .03
Diabetes mellitus, %, (n) 10% (1/10) 8% (5/59) 1.00
Hypogonadism, % (n) 20% (2/10) 5% (3/59) .15
Considerable alcohol intake†, % (n) 20% (2/10) 23% (13/57) 1.00
Year of diagnosis (Q1, Q3) 2001 (1990, 2003) 1998 (1994, 2006) .55
Values are means±1 standard deviation (SD) for normally distributed values and medians with ﬁrst and third quartile for non-normally distributed values.
HCC=hepatocellular carcinoma, HH=hereditary hemochromatosis, MCP=metacarpophalangeal.
∗
Liver ﬁbrosis is deﬁned as either cirrhosis or severe, portal-portal bridging ﬁbrosis.
† Considerable alcohol intake is deﬁned as consumption of >1 standard drink (=10g ethanol) per day for women and >2 standard drinks for men.
Table 4
Multiple logistic regression comparing patients with and without hepatocellular carcinoma.
95% CI for B
B Standard error Lower Upper Exp (B) P
Age at diagnosis 0.174 0.069 0.056 0.397 1.190 .001
Male sex 0.365 1.661 2.874 5.457 1.440 .83
Serum ferritin 0.000 0.000 0.001 0.001 1.000 .79
Elevated liver enzymes 2.683 1.716 0.193 7.974 14.636 .07
Considerable alcohol intake
∗
0.125 1.227 2.517 2.524 1.133 .92
MCP-arthropathy 0.075 1.038 2.095 2.330 1.078 .94
Body mass index 0.196 0.166 0.116 0.580 1.217 .23
HCC=hepatocellular carcinoma, MCP=metacarpophalangeal.
∗
Considerable alcohol intake is deﬁned as consumption of >1 standard drink (=10g ethanol) per day for women and >2 standard drinks for men.
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age at diagnosis was still signiﬁcantly higher among HCC patients
[Exp(B)1.213,P= .007; total of 40caseswere analyzed].Theother
variables did not differ signiﬁcantly. We further compared HCC
patients with patients without HCC and very high ferritin levels
(>2000mg/L), which corresponds to amatched population for this
variable.Ageat diagnosiswas still signiﬁcantlyhigher amongHCC
patients (60.5±11 vs 48.4±7.8 years; P= .001). Likewise, when
including only patients with positive liver histology, HCC patients
were signiﬁcantly older than non-HCC patients (63.5±16 vs 50.0
±7 years; P= .004).
3.4. Other malignancies
During the follow-up time, 14 other malignancies than HCC
occurred in 13 hemochromatosis patients: 3 lung cancers, 3
prostate cancers, 2 tonsil cancers, 1 kidney cancer, 1 testicular
cancer, 2melanomas, 1 spinocellular carcinoma, and 1 basalioma.
One patient with 2 malignancies had melanoma and basalioma.
Serum ferritin levels at diagnosis of hemochromatosis were not
signiﬁcantly different in patients who developed other malignan-
cies compared with the other patients (2085±2748 vs 1840±
1683mg/L; P= .17). In patients with serum ferritin levels above
and under 1000mg/L, other malignancies occurred with a similar
frequency (P= .32). In the univariate regression analysis, serum
ferritin levels at diagnosis were not predictive for the development
of other malignancies (odds ratio 1.0; 95% CI 1.00–1.001;
P= .08).
4. Discussion
In this large, well-deﬁned cohort of HH patients, all with
genetically proven diagnosis, with a very long follow-up time, we
found that HCC, occurring in 9% of all HH patients, is still a
prevalent HH complication.
Higher age at diagnosis was the strongest predictor of HCC
development in this cohort. It seems to be a surrogate marker for
the duration of exposure to iron overload, because progressive
accumulation of iron with increasing age is assumed in patients
without iron depletion therapies.[26] In our analyses, the high iron
overload, expressed by the serum ferritin levels of above 1000mg/
L, lost its signiﬁcance in the multiple logistic regression analysis
after adjustment for age at diagnosis. This ﬁnding suggests that
the duration of exposure to toxic iron levels may be more
important for the development of HCC than the amount of the
liver iron burden.
Another risk factor for HCC in this cohort was a high iron
overload, reﬂected by the serum ferritin levels of above 1000mg/L
at diagnosis. There are several pathological and experimental
studies providing evidence for the direct carcinogenic effects of
iron through oxidative stress and epigenetic DNA, lipid, and
protein modiﬁcations, which lead to hepatocyte necrosis and
apoptosis.[11,20] In addition, the mutagenic radicals, generated by
oxidative stress, may suppress the immune response against
formation of malignant hepatocytes, either directly or via
inﬂammation pathways.[20,27] Furthermore, iron overload has
been shown to cause insulin resistance which can enhance HCC
development.[28] This effect was independent of the presence of
cirrhosis.[29–32] Also in our cohort, 1 patient who developedHCC
had no liver cirrhosis and a normal liver biopsy at baseline.
Some previous studies also found an overall prevalence of
HCC of 8% to 10% and a high prevalence among patients with
cirrhosis.[9,13,17,21] Interestingly, the prevalence of HCC among
HH patients remained similar over the last 40 years.
Importantly, the development of liver cirrhosis has been shown
to correlate with the severity of iron overload in previous
studies.[21,33] Along the same lines, HCC patients had signiﬁ-
cantly higher ferritin levels at diagnosis in our and also in
previous studies. In contrast to other studies, we could not ﬁnd a
signiﬁcant association between considerable alcohol consump-
tion and development of HCC. A possible explanation could be
the low prevalence of a heavy alcohol intake in our cohort (only 5
patients who consume >300g of ethanol per week), at least as
self-reported.
If HCC is diagnosed at a symptomatic stage, a poor prognosis
can be expected, because curative surgical or interventional
options are limited.[34] Thus, screening of high-risk populations is
recommended to detect HCC at an early stage.[35,36] So far,
American Association for the Study of Liver Diseases guidelines
recommend regular screening for HCC in patients with liver
cirrhosis only.[35] We, however, recommend regular screening
also in patients who were diagnosed and initiated on iron
depletion therapy at a higher age and had/or a high iron overload
(>1000mg/L) at diagnosis. In these patients, liver ultrasonogra-
phy at 6-month intervals should be the preferable screening
method. In patients with a moderate (<1000mg/L) iron overload
and without cirrhosis, we use to perform liver ultrasonography at
12-month intervals. Screening in noncirrhotic livers can aid in the
early diagnosis of HCC in the cases where HCC develops without
cirrhosis. Screening intervals in patients with moderate iron
overload without cirrhosis can be individually determined in
discussion with the patient, depending on availability of other
risk factors. Screening should be continued throughout life
because HCC can develop many years after the achievement of
iron depletion.[21]
The biomarker alpha-fetoprotein (AFP) is less helpful for HCC
diagnosis because of its low sensitivity and speciﬁcity, especially
with small sizes of HCC: AFP levels remain normal in up to 40%
of patients with HCC, particularly during the early stage of the
disease.[37]
Interestingly, iron overload was not signiﬁcantly associated
with the occurrence of the other malignancies during the
follow-up time in this study. However, this ﬁnding is
limited because no screening programs for malignancies,
other than HCC, are established in hemochromatosis. Thus,
a number of other malignancies could have remained
undiagnosed.
Several limitations merit consideration: only 70 of 147 patients
in the cohort underwent liver biopsies. This is an increasingly
common limitation because liver biopsy is no longer needed to
assess liver iron content, which nowadays can be done
noninvasively by MRI.[38] Similarly, although we saw an
association of increased BMI with HCC, which have been
previously observed and associated with nonalcoholic fatty liver
disease (NAFLD),[39] we cannot make a statement in this regard
from our study due to the lack of information about NAFLD in
biopsy specimens. Furthermore, no conclusion can be made from
our study about the inﬂuence of concurrent chronic viral
hepatitis, as only 3 patients (all without HCC) suffered from
chronic hepatitis B or C.
The strength of the study is that we recruited patients not only
from a tertiary care center, but also from the primary care. Thus,
we consider the cohort to adequately reﬂect the clinical picture of
HHencountered in daily practice. Furthermore, in this prospective
cohort, we applied regular patient assessment, and included the
collection of complete clinical, biochemical, genetic, and pheno-
typic information. These advantages were frequently lacking in
Nowak et al Medicine (2018) 97:42 www.md-journal.com
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other studies. Also, this homogeneous study population was
exposed to the same environmental conditions due to medical
treatment and geographic and cultural proximities.
5. Conclusions
Higher age at diagnosis showed the strongest association with the
occurrence of HCC in Swiss hemochromatosis patients. Early
diagnosis and therapy initiation beneﬁt the disease course and
help to prevent HCC. Patients who were diagnosed having HH at
a higher age and with a high iron overload, expressed by the
serum ferritin levels of >1000mg/L, are at increased risk to
develop HCC and require regular screening even if they have no
liver cirrhosis.
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